Interleukin-28A promotes IFN-γ production by peripheral blood mononuclear cells from patients with Behçet's disease

Cellular Immunology

Volumn 290, Issue 1, 2014, Pages 116-119

  Li, Bing ^a   Xie, Chufang ^a   Lin, Xiaomin ^a   Su, Shao Bo ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Beh et's disease; Cytokine; IL 28A; PBMCs

Indexed keywords

CHLORAMBUCIL; CORTICOSTEROID; CYCLOSPORIN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 28A; INTERLEUKIN 4; MESSENGER RNA;

ADULT; APHTHOUS STOMATITIS; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION; GENITAL ULCER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IRIDOCYCLITIS; MALE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA VASCULITIS; SKIN DEFECT;

BEHÇET'S DISEASE; CYTOKINE; IL-28A; PBMCS;

ADULT; BEHCET SYNDROME; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-4; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RNA, MESSENGER; TH17 CELLS; YOUNG ADULT;

EID: 84903136320     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2014.06.003     Document Type: Article

References (34)

1. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 2003, 4:69.
2. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 2003, 4:63.
3. Siren J., Pirhonen J., Julkunen I., Matikainen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J. Immunol. 2005, 174:1932.
4. Robek M.D., Boyd B.S., Chisari F.V. Lambda interferon inhibits hepatitis B and C virus replication. J. Virol. 2005, 79:3851.
5. Ank N., Iversen M.B., Bartholdy C., Staeheli P., Hartmann R., Jensen U.B., et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J. Immunol. 2008, 180:2474.
6. Numasaki M., Tagawa M., Iwata F., Suzuki T., Nakamura A., Okada M., et al. IL-28 elicits antitumor responses against murine fibrosarcoma. J. Immunol. 2007, 178:5086.
7. Sato A., Ohtsuki M., Hata M., Kobayashi E., Murakami T. Antitumor activity of IFN-lambda in murine tumor models. J. Immunol. 2006, 176:7686.
8. Li W., Lewis-Antes A., Huang J., Balan M., Kotenko S.V. Regulation of apoptosis by type III interferons. Cell Prolif. 2008, 41:960.
9. Maher S.G., Sheikh F., Scarzello A.J., Romero-Weaver A.L., Baker D.P., Donnelly R.P., et al. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol. Ther. 2008, 7:1109.
10. Siebler J., Wirtz S., Weigmann B., Atreya I., Schmitt E., Kreft A., et al. IL-28A is a key regulator of T-cell-mediated liver injury via the T-box transcription factor T-bet. Gastroenterology 2007, 132:358.
11. Sakane T., Takeno M., Suzuki N., Inaba G. Behcet's disease. N. Engl. J. Med. 1999, 341:1284.
12. Saadoun D., Cassoux N., Wechsler B., Boutin D., Terrada C., Lehoang P., et al. Ocular manifestations of Behcet's disease. Rev. Med. Interne 2010, 31:545.
13. Yang P., Zhang Z., Zhou H., Li B., Huang X., Gao Y., et al. Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China. Curr. Eye Res. 2005, 30:943.
14. Li B., Yang P., Zhou H., Zhang Z., Xie C., Lin X., et al. T-bet expression is upregulated in active Behcet's disease. Br. J. Ophthalmol. 2003, 87:1264.
15. Luger D., Silver P.B., Tang J., Cua D., Chen Z., Iwakura Y., et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J. Exp. Med. 2008, 205:799.
16. Amadi-Obi A., Yu C.R., Liu X., Mahdi R.M., Clarke G.L., Nussenblatt R.B., et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat. Med. 2007, 13:711.
17. McGonagle D., McDermott M.F. A proposed classification of the immunological diseases. PLoS Med. 2006, 3:e297.
18. Geri G., Terrier B., Rosenzwajg M., Wechsler B., Touzot M., Seilhean D., et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behcet disease. J. Allergy Clin. Immunol. 2011, 128:655.
19. Criteria for diagnosis of Behcet's disease. International study group for Behcet's disease. Lancet 1990, 335:1078.
20. Brand S., Beigel F., Olszak T., Zitzmann K., Eichhorst S.T., Otte J.M., et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289:G960.
21. Meager A., Visvalingam K., Dilger P., Bryan D., Wadhwa M. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 2005, 31:109.
22. Zitzmann K., Brand S., Baehs S., Goke B., Meinecke J., Spottl G., et al. Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. Biochem. Biophys. Res. Commun. 2006, 344:1334.
23. Koltsida O., Hausding M., Stavropoulos A., Koch S., Tzelepis G., Ubel C., et al. IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol. Med. 2011, 3:348.
24. Tsai H.C., Velichko S., Hung L.Y., Wu R. IL-17A and Th17 cells in lung inflammation: an update on the role of Th17 cell differentiation and IL-17R signaling in host defense against infection. Clin. Dev. Immunol. 2013, 2013:267971.
25. Yoshimura T., Sonoda K.H., Miyazaki Y., Iwakura Y., Ishibashi T., Yoshimura A., et al. Differential roles for IFN-gamma and IL-17 in experimental autoimmune uveoretinitis. Int. Immunol. 2008, 20:209.
26. Witte K., Gruetz G., Volk H.D., Looman A.C., Asadullah K., Sterry W., et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 2009, 10:702.
27. Sommereyns C., Paul S., Staeheli P., Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 2008, 4:e1000017.
28. Pekarek V., Srinivas S., Eskdale J., Gallagher G. Interferon lambda-1 (IFN-lambda1/IL-29) induces ELR(-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner. Genes Immun. 2007, 8:177.
29. Mennechet F.J., Uze G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006, 107:4417.
30. Dai J., Megjugorac N.J., Gallagher G.E., Yu R.Y., Gallagher G. IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood 2009, 113:5829.
31. Chi B., Dickensheets H.L., Spann K.M., Alston M.A., Luongo C., Dumoutier L., et al. Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J. Virol. 2006, 80:5032.
32. Jordan W.J., Eskdale J., Boniotto M., Rodia M., Kellner D., Gallagher G. Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes Immun. 2007, 8:13.
33. Gallagher G., Megjugorac N.J., Yu R.Y., Eskdale J., Gallagher G.E., Siegel R., et al. The lambda interferons: guardians of the immune-epithelial interface and the T-helper 2 response. J. Interferon Cytokine Res. 2010, 30:603.
34. Contoli M., Message S.D., Laza-Stanca V., Edwards M.R., Wark P.A., Bartlett N.W., et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat. Med. 2006, 12:1023.